What evaluations should be performed to assess DUOX2-related thyroid dyshormonogenesis?

DUOX2 Evaluation: Re-evaluation Off Treatment is Mandatory

For patients with confirmed DUOX2 mutations causing congenital hypothyroidism, you must perform re-evaluation of thyroid function off treatment, unlike other forms of dyshormonogenesis, because DUOX2-related CH can be transient. 1

Why DUOX2 is Different

DUOX2 mutations are explicitly listed as an exception to the general rule that dyshormonogenesis doesn't require re-evaluation. The European Society for Paediatric Endocrinology guidelines specifically state that re-evaluation is NOT indicated when dyshormonogenesis is confirmed by molecular testing, "with the exception of DUOX2 mutations or Pendred syndrome" 1. This is because:

• Transient CH is common with DUOX2 variants, particularly heterozygous mutations 1
• Up to one-third of patients with normally located glands may have transient dysfunction 1
• Clinical heterogeneity is substantial—identical genotypes can produce divergent outcomes (transient vs. permanent) 2

Specific Evaluation Protocol

Timing of Re-evaluation

• After age 3 years is the standard recommendation 1
• Earlier re-evaluation (from age 1 year) may be considered if:
  • Eutopic, normally sized thyroid gland on ultrasound 1
  • No increase in L-T4 dose required since infancy 1
  • Clinical context suggests high probability of transient disease 1

Withdrawal Protocol

• Phase out L-T4 over 4-6 weeks before testing 1
• This allows accurate assessment of endogenous thyroid function

What to Monitor During Re-evaluation

• TSH and FT4 levels after treatment withdrawal 1
• Thyroid imaging (ultrasound for morphology) 1
• Note: Baseline TSH, T4, FT4, thyroid volume, and bone maturation at diagnosis do NOT reliably predict who will recover 2

Clinical Pitfalls

Common mistake: Assuming biallelic DUOX2 variants always mean permanent CH. Recent evidence shows that even patients with biallelic pathogenic variants can discontinue treatment, and baseline biochemical severity doesn't predict outcome 2. Conversely, some monoallelic (heterozygous) carriers may have permanent disease 3, 4.

Genotype-phenotype correlation is poor: Identical DUOX2 genotypes can result in transient or permanent CH, suggesting modifying factors or compensatory H2O2-generating pathways 2, 4. Therefore, empiric re-evaluation is mandatory regardless of mutation severity.

Associated Findings to Check

• Thyroid morphology: DUOX2 biallelic variants typically associate with goiter 5, though monoallelic variants can associate with hypoplasia or agenesis 5
• Initial TSH levels: May be less severe than TPO-related CH 5
• L-T4 dose requirements: Often lower than other dyshormonogenesis forms 3
• Digenic variants: 26.67% of DUOX2 patients may have variants in other thyroid genes 4, which could modify phenotype

Bottom line: Unlike other confirmed dyshormonogenesis, DUOX2 mutations mandate re-evaluation off treatment after age 3 years (or earlier if clinical context suggests transient disease) because permanent vs. transient status cannot be predicted from genotype, initial biochemistry, or imaging alone.